Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Ranibizumab in Neovascular AMD
NCT00095433Phase 3Completed
- Sponsor
- Genentech
- Start
- Sep 2002
- Primary completion
- Aug 2006
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Genentech. Started Sep 2002; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00095433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095433.